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Introduction 
 
 
 
 
INTRODUCTION 
 Cirrhosis of liver is the tenth leading cause of death in India and a 
major cause of disease burden among the population. The expenditure in 
treatment not only burns out the country’s economic resources but also a 
major cause of sickness absenteeism leading to man days losses. 
 According to the latest WHO data published in May 2014 “Deaths 
due Liver Disease” and its complications in  India is killing almost 
216,865 people and accounts for nearly 2.44% of total deaths and India  
ranks 61 among the other world nations in mortality due to cirrhosis 
 The disease course is further altered by the development of 
numerable complications like varices, hepatic encephalopathy, 
coagulopathy, hepatopulmonary syndrome, cirrhotic cardiomyopathy, 
hepatorenal syndrome that carries a poor prognosis. 
 Among the various complications the development of hepatorenal 
syndrome has a devastating course and outcome in cirrhotic patients.  
HRS is usually an extended spectrum of prerenal azotemia and therefore 
is potentially reversible. 
 But after the evolution of the disease, the median survival is only 2 
weeks without liver transplantation or management with vasoconstrictors. 
 
 
 HRS is a part of events occurring in the background of cirrhosis 
with PHT or acute liver injury.  
Two important pathogenesis of HRS 
 Splanchnic arterial  vasodilatation  
 Renal  arterial  vasoconstriction 
 This leads to progressive renal failure with normal kidneys in 
histological examination.3 
 Usually HRS can be diagnosed only after the rise in blood urea 
nitrogen and serum creatinine. By then the disease has progressed so that 
it is no longer reversible and has a poor outcome. But the disease can be 
predicted in advance by the estimation of renal resistive index that 
increases before a considerable period of time by Doppler ultrasound and 
so measures can be implemented to prevent the disease progression by 
avoiding the excess use of diuretics and nephrotoxic agents, avoiding 
large volume paracentesis etc. 
 Renal dysfunction may be corrected by treating of portal 
hypertension, liver transplantation, transplantation of the kidneys into a 
noncirrhotic recipient, and medical management. 4 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims & Objectives 
 
 
 
 
AIMS AND OBJECTIVES 
 To measure the intrarenal resistive index in patients with liver 
cirrhosis. 
 To estimate  the renal  vasoconstriction before overt hepatorenal  
syndrome   develops in cirrhotic patients  with  and without  ascites 
 To  compare  the  resistive  index  with  MELD and  Child Pugh 
scoring  system 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature 
 
 
 
 
REVIEW OF LITERATURE 
 Hepatorenal  syndrome  has  its  original  description  that dates as  
far back  in  late  19th  century  when  Frerichs  and  Flint  reported  some  
cases of    renal  failure  occurring  in  patients  with  end  stage  liver 
disease.5 
 In 1932, Helvig and Schutz coined the term “liver and kidney 
syndrome,” to illustrate the type of acute kidney injury that happened 
after abiliary surgery.6 
 But it was in 1956, Hecker and Sherlock gave the clinical 
definition of HRS characterised by hyponatremia, oliguria, absence of 
proteinuria, reduced urinary sodium excretion.7All  the  patients  
succumbed  to  the  illness  and findings  in  post-mortem  revealed 
normal renal histology. Then they postulated the underlying mechanism 
as “peripheral vasodilatation”. 
 Later  reports  of   reversal  of  renal  function  when  
transplantation  of kidneys  from  patients  with  end  stage  liver  disease  
to   recipients  of  end stage  kidney  disease  proved the  previously  
postulated  theories 
 
 
 
 
CIRRHOSIS 
The terminology "cirrhosis" is derived from the Greek word “kirrhos” 
and “osis” in the year 1830. 
 “Kirrhós” means "yellowish or  tawny" because of the 
yellowish colour imparted to the  diseased liver 
 “Osis” means “condition" in medical term 
   In 1826, Laennec coined the term "cirrhosis".8 
   In 1930, Roessle explained the pathogenesis of cirrhosis  
Cirrhosis is a diffuse process characterised by three processes9 
 Fibrous  septae bridging the portal tracts 
 Nodular  transformation 
 Hepatic architectural disruption. 
 
 BRIDGING SEPTAE 
 
MACRONODULES 
 
 
 
                       Figure 1: Cirrhosis histology 
 
 
DISEASE PROGRESSION IN CIRRHOSIS 
 Chronic liver damage results in a spectrum of hepatocellular injury 
ranging from fatty infiltration and hepatitis progressing to cirrhosis and 
hepatocellular carcinoma.10 
It is characterised by  
 Hepatic  steatosis 
 Necro-inflammation  with  fibrosis 
 Nodular degeneration 
FATTY LIVER 
 Benign condition caused by accumulation of lipid within the 
hepatocyte. 
 Earliest and predictable response to consumption of alcohol. 
 Usually reverses with abstinence. 
 10 % risk  of  developing  cirrhosis  in  heavy  drinkers.11 
ALCHOHOLIC  HEPATITIS 
 10% to 35% of heavy drinkers.  
 Formation of necro-inflammation, with or without steatotic 
changes and fibrosis which is a  natural wound-healing response. 
 
 
 Destruction of the sinusoids, the space of Disse, vascular structures 
that initiate the occurrence of resistance to blood flow in the liver. 
Alcoholic hepatitis is a specific and important clinical condition as 
patients with severe alcoholic hepatitis have     
 Increased short-term mortality rates. 
 Alcoholic hepatitis is a clearly defined precursor of cirrhosis. 
 Risk  is  nine times  increased  than  with fatty  liver alone.11 
CIRRHOSIS  
 Maladaptive wound healing response & remodelling of scar tissue 
MICRONODULAR: 
 Also called  as  Laennec cirrhosis 
 8% to 20% in individuals with heavy consumption of alcohol. 
 Fine mesh-like pattern develops with prominent  entanglement of  
the central vein  
MACRONODULAR: 
 Progressively transforms  to  form broad bands of fibrosis that  
split large nodules of liver tissues 
 Hepatocellular carcinoma develops in this setting.  
 
 
 
MORPHOLOGICAL CHANGES OCCURRING IN 
DEVELOPMENT OF CIRRHOSIS 
 
 
Figure 2: Morphological changes occurring in 
development of cirrhosis 
 
 
HISTOPATHOLOGICAL CHANGES IN THE 
DEVELOPMENT OF CIRRHOSIS 
NORMAL LIVER 
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Figure 3: Histopathological changes of cirrhosis  
 
 
PATHOGENESIS OF CIRRHOSIS12,13,14,15 
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Figure 4: Pathogenesis of cirrhosis 
 
ETIOLOGY OF CIRRHOSIS16 
 
Table 1: Etilogy of Cirrhosis 
 
 
 
CLINICAL FEATURES 
 Fatigue, weakness, anorexia, weight loss.17 
 DIRECT CONSEQUENCE OF LIVER CELL FAILURE 
 Jaundice17 
 Parotid enlargement 
 Palmar erythema18 
 Spider naevi19 
 Hypogonadism20 
 Gynecomastia21 
 Fetor hepaticus 22 
 Enlarged liver or shrunken liver 
 Ascites 
  CONSEQUENCES OF  PORTAL HYPERTENSION 
 Haemetemesis  as  a result  of  esophageal  varices 
 Splenomegaly 23 
 Caput medusa 
MISCELLANEOUS FEATURES  
 Hypoalbunemia induced nail changes24 
 Muehrcke's lines and Terry  nails 
 Clubbing and Hypertrophic osteoarthropathy.24 
 Dupuytren's contracture 
 
 
END STAGE LIVER DISEASE 
  Bleeding diathesis 
 Hepatic encephalopathy 
 Acute kidney injury 
LABORATORY FINDINGS IN CIRRHOSIS 
LIVER ENZYMES:25 
 Serum aminotransferases 
 Modest elevation of (ALT) & (AST) even in severe 
alcoholic hepatitis and cirrhosis. 
 Alkaline phosphatase  
 Primary biliary cirrhosis  
  Primary sclerosing  cholangitis 
 Gamma-glutamyl transpeptidase (GGT) 
 Alcohol induced chronic liver disease. 
 With alcohol abuse, even in the absence of liver disease due 
to    microsomal enzyme induction. 
 Serum Bilirubin : Normal in compensated cirrhosis and 
increased levels as cirrhosis progresses. 
 Coagulation defects : Prolonged Prothrombin time 
 Serum albumin : Reduced  because albumin is synthesized only 
in the liver 
 
 
 Serum globulins: Increased because of shunting of bacterial 
antigens from liver to lymphoid tissue. 
 Reversal of albumin-globulin ratio 
 Hyponatremia  
 High levels of ADH and aldosterone. 
 Inability to excrete free water. 
 Correlates with severity of disease.14 
HAEMATOLOGICAL ABNORMALITIES26 
 Anemia 
 Marrow suppression 
 Bleeding from varices 
 Leukopenia and neutropenia  
 Due to splenomegalyand  splenic sequestration. 
 Thrombocytopenia  
 Alcoholic marrow suppression 
 Sepsis 
 Lack of folate 
 Sequesteration in the spleen  
 Decreased thrombopoietin. 
 
 
 
 
OTHERS 
 Serology for hepatitis viruses. 
 Autoantibodies (ANA,  anti-LKM) 
 Markers of iron and copper overload, alpha 1 antitrypsin. 
IMAGING 
ULTRASONAGRAPHY OF ABDOMEN:27,28 
 Non-invasive test.    
 Screening of hepatocellular carcinoma 
 Patency of the portal vein  
 Presence of ascites, splenomegaly. 
 
 
 
 
 
Figure 5: Ultrasound image 
 
 
 
FIBROSCAN 29 
 Transient elastography . 
 Non – invasive method for evaluation of liver fibrosis and  
cirrhosis. 
 
 
 
 
 
Figure 6: Fibroscan Score 
LIVER BIOPSY 30 
 Gold standard for diagnosis  
 Diagnosis of the aetiology 
 Sensitivity is 80-100% 
PROGNOSTIC SCORES FOR CIRRHOSIS 
 Child Turcotte Pugh classification (CPC) 
 Model for End stage Liver Disease (MELD) 
 
 
 
CHILD-TURCOTTE-PUGH CLASSIFICATION 
 In assessment  of  prognosis  of  liver  disease.31 
 Predicting  the  survival rates 
 
Table 2: Child – Turcotte-Pugh Classification 
 
 MELD SCORE 
 To prioritize patients for transplantation.32 
 It is calculated according to the following formula:33 
 
 
 
 
 
INTERPRETATION34 
 3 month mortality is:  
 40 or more — 71.3% mortality 
 30–39 — 52.6% mortality 
 20–29 — 19.6% mortality 
 10–19 — 6.0% mortality 
 <9 — 1.9% mortality 
COMPLICATIONS OF CIRRHOSIS 
PORTAL HYPERTENSION 
 GastroesophagealVarices 
 Portal Hypertensive Gastropathy 
 Ascites 
 Spontaneous Bacterial Peritonitis 
 Hepatic Encephalopathy 
 Hepatorenal Syndrome 
 Hepato Pulmonary Syndrome 
 Cirrhotic Cardiomyopathy 
 Portopulmonary Hypertension 
 Splenomegaly ,Hypersplenism 
 
 
HAEMATOLOGICAL ABNORMALITIES 
 Anaemia  
 Leucopenia 
 Thrombocytopenia 
                          CAUSES OF ANEMIA IN LIVER DISEASE   
 
EFFECTS OF LIVER DISEASE IN HEMOSTATIC MECHANISM 
 
 
PORTAL HYPERTENSION 
  HVPG greater than or equal to 5mm Hg  
 Significant varices develop at HVPG of 10 mm Hg.35 
 
Figure 8: Pathogenesis of Portal Hypertension 
 
 
 
 
Figure 9: Causes of PHT 
 
 
 
 
 
 
VARICEAL HAEMMORHAGE 
 Esophageal varices is dreadful complication of PHT. 
 Most common cause of  UGI bleed in one third of cirrhotics. 
 Incidence 5–15% / per year.36 
 Portal hypertension leads to formation of portosystemic collaterals 
and varices. 
 
 
 
 
Figure 10: Varices. 
 
 
ASCITES 
 
 
 
Figure 11: Mechanisam of formation of Ascites 
 
 
 
 
 
 
 
SPONTANEOUS BACTERIAL PERITONITIS 
 Spontaneous infection of fluid in abdominal cavity without an 
intraabdominal source of infection. 
 Incidence - 30%  
 Most common organism is E.Coli. 
Figure 12: Pathophysiology of Spontaneous Bacterial Peritonitis 
 
 
 
 
HEPATIC ENCEPHALOPATHY 
 
 
 Wide  range  that encomposess transient and reversible 
neurological  and psychiatric manifestations.36 
 Occurs  in  chronic liver disease with portal hypertension andacute 
liver failure. 
 Incidence 50% to 70% in  patients with cirrhosis 
 Poor  prognostic indicator. 
 Three year survival rate 42%, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Mechanisam of Hepatic Encephalopathy 
 
 
 
PATHOGENESIS OF HRS, HPS, CIRRHOTIC 
CARDIOMYOPATHY HEPATORENAL SYNDROME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Pathogenesis of HRS, HPS, Cirrhotic Cardiomyopathy 
Hepatorenal Syndrome 
 
 
HEPATORENAL SYNDROME 
 Hepatorenal syndrome (HRS) is  a  distinct form of functional renal 
failurethat  occurs  as  a  part  of  cascade  of  events  related  to  the  
intense  dilatation of  splanchnic  bed  in  the  background  of  cirrhosis  
with  ascites or  acute fulminant   hepatic  failure  leading  to  
vasoconstriction  of  renal  arterial  bed and  progressive  renal  failure  
with  normal  renal  histology.37 
 Koppel et al. identified the reversal of the renal failure when 
kidneys of patients with advanced liver disease and HRS transplanted to 
the recipients with end-stage renal disease with normal liver function 38 
 The  outcome  is  very  poor  and  mean  survival  is  only  weeks  
to  months. Due to the absence of diagnostic biomarkers, the diagnosis of 
HRS lies in the combination of clinical and laboratory informative data. 
COURSE OF THE DISEASE 
 
 
 
 
Figure 15: Course of the Disease 
 
 
CLASSIFICATION OF HEPATORENAL SYNDROME 
TYPE 1HRS 
 Renal  dysfunction  which  is  rapidly  progressive  with  doubling 
of the serum creatinine to a value > 2.5 mg/dL in less than two 
weeks.39 
 Associated  with  a  precipitating  factor  like spontaneous  
bacterial  peritonitis,  GI  bleeding,  acute  liver   insult. 
 Rapid  decline  of  circulatory  ,  hepatic and  renal  functions 
TYPE 2 HRS  
 Renal  dysfunction  which  is  steadily progressive   with  serum 
creatinine > 1.5 and up to 2.5mg/dL or over weeks to months39 
 Usually occurs in refractory ascites. 
 Gradual  decline  of  circulatory  and  renal  functions 
TYPE 3 HRS 
 HRS occurring  in cirrhotic  patients  having  chronic renal 
disease40 
TYPE 4 HRS 
 HRS  superimposed  on  fulminant hepatic  failure  
 More than 50% of acute fulminant liver failure develop HRS 
 
 
 DIAGNOSTIC CRITERIA 
In 1996   International Ascites Club (IAC) produced diagnostic criteria 
for HRS that was accepted internationally.41 
REVISED DIAGNOSTIC CRITERIA FOR HEPATORENAL 
SYNDROME DEFINED BY IAC CONSENSUS WORKSHOP IN 
THE YEAR 200742 
 
 
 
 
 
EPIDEMIOLOGY 
 Annual  incidence  - 7.6% 
 Prevalence             - 45.8% 
 Age                        -6 th or 7th decade.  
 Gender                   - Increased   male preponderance 43 
HRS   predominantly  occurs  in  individuals with  cirrhosis  and  ascites 
with elevated  pressure  in  the  portal  vein.  
 INCREASED  INCIDENCE 
 Alcoholic  cirrhosis 
 Coexisting acute severe alcoholic hepatitis increases  the  risk..44 
 Fulminant  hepatic  failure(55%).45 
 RISK  FACTORS 
 Low mean arterial blood pressure (< 80 mm Hg). 
 Dilutional hyponatremia. 
 Urinary sodium retention (urine sodium < 5 mEq/L) 
 
 
 
 
 
 
PRECIPITATING   FACTORS 
SPONTANEOUS BACTERIAL PERITONITIS (SBP).  
SBP has a definitive correlation   with HRS 46 
 
Figure 16: Pathophysiology of Spontaneous Bacterial Peritonitis 
 
 
 
 
SBP trigger HRS by two mechanisms 47,48 
 Release of endotoxins and proinflammatory cytokines (IL-6 and 
TNF) leading to increased production of NO and other 
vasodilators. 
 Sepsis – related cardiomyopathy leading to reduced cardiac output. 
LARGE VOLUME PARACENTESIS WITHOUT 
PLASMA EXPANSION. 
 LVP  aggravate  hyperdynamic circulation that leads to enhanced  
systemic vasodilation and arterial underfilling.49 
 Rapid  formation  of  ascitic  fluid  after  a  large volume  
 paracentesis  leads  to  decreased  circulating  blood  volumeand 
 reduced  renal  perfusionprecipitating  acute  renal  failure. 
 
 
 
 
 
 
Figure 17: LVP 
 
 
GASTROINTESTINAL   BLEEDING50 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Susceptibility  to  infection  increases  after  a  GI  bleed  leading  to  
cytokine  storm,  further  rebleeding  and  follows  a  vicious  cycle 
INITIATE  A SYSTEMIC INFLAMMATORY 
RESPONSE 
 ACTIVATION  OF CASCADE  OF 
PROINFLAMMATORY CYTOKINES 
STIMULATION OF NO  AND  OTHER  
VASODILATORS 
 
SPLANCHNIC  VASODILATATION 
RENAL  VASOCONSTRICTION 
HEPATORENAL  SYNDROME 
 
 
NSAIDs 
 NSAIDs   worsens   HRS  in  individuals with  borderline  renal  
function  as  initially  the  renal  vasoconstriction  is  counterbalanced  by  
PGs 
DIURETICS 
 Injudicious use of   diuretics leads to intravascular volume 
depletion and  triggers HRS. 
BILIARY OBSTRUCTION 51 
 Precipitate   HRS by  two mechanism 
1. Increased bile acids  
 Alter renal handling of water and electrolytes by blocking sodium-
hydrogen antiport protein . 
2. Oxidative stress 
 Production of vasoconstrictor substances. 
PREDICTORS OF HRS 
 No  hepatomegaly, 
 Increased  plasma renin activity, 
 Reduced  serum sodium52 
 
 
 
RENAL  RESISTIVE  INDEX53 
 Indicator  of  intrarenal  vascular  tone 
 Intrarenal  resisitive  index  predicts  the  development  of  renal 
vasoconstriction  in  end  stage  cirrhotics. 
Renal dysfunction occurs in patients when RI is elevated from a baseline 
(≥0.7). 
PATHOPHYSILOGY 
The initiation and perpetuation of HRS is complicated and poorly 
understood. 
Three components leading to the evolution of HRS are 
 Splanchnic  vasodilatation  
 Renal  vasoconstriction  
 Cardiac  dysfunction 
 
 
PATHOPHYSILOGY OF HEPATORENAL SYNDROME
 
 
Figure 18: Pathophysilogy of Hepatorenal Syndrome 
  
 
 
SPLANCHNIC VASODILATATION 
In 1970, Epstein et al. demonstrated the importance of splanchnic 
vasodilation with renal vasoconstriction as a  concept in the 
pathophysiology of HRS .54 
 Nitric  oxide  and  other  vasodilator substances such as 
carbonmonoxide, glucagon, vasodilator peptides  mediate  
vasodilatation  of  splanchnic  arterial  bed  in a cirrhotic  liver.55 
 
Figure 19: Splanchnic Vasodilatation 
 
 
 Sequestration of blood in the splanchnic arterial   bed leads   to 
decreased effective arterial blood volume (“arterial underfilling”) 
and  blood  pressure.  
 In compensated cirrhosis, heart  rate and cardiac output increases 
and  creates  a  hyperdynamic  circulation56 
 Decompensated cirrhosis ensues as the liver disease progresses and 
splanchnic vasodilation progresses leading to permanent decrease 
in   effective arterial blood volume. 
 
Figure 20: Renal Vasoconstriction 
 
 
RENAL VASOCONSTRICTION 
 Schroeder et al., Arroyo et al., and Ring-Larsen et al. contributed to  
the role of neurohormonal vasoconstrictor pathways (RAAS and SNS) in 
the development  of HRS .57 
 Splanchnic and systemic arterial vasodilatation   leads retention of 
sodium and free water by 
 Activation  of the RAAS  and  SNS  
 Non   osmotic  release  of  AVP  that occurs in decompensated  
cirrhosis 
 Altered   production  endothelins,  prostaglandin,  
kallikreins,  and  F2  isoprostanes.58-60 
CARDIAC  DYSFUNCTION 
 
Figure 21: Cardiac Dysfunction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Schematic representation 
 
 
CLINICAL MANIFESTATION 
There are no specific clinical findings for HRS. 
 Usually it is related to the 
1. Severity  of  liver  disease 
2. Degree  of   renal  dysfunction 
3. Hemodynamic   abnormalities. 
1. CLINICAL MANIFESTATIONS  RELATED  TO  LIVER  
DISEASE 
 Constitutional disturbances. 
 Jaundice 
 Ascites 
 Features  of portal hypertension (e.g., GI varices,splenomegaly 
hepatic encephalopathy). 
 Coagulopathy 
 Finger clubbing 
 Palmar erythema 
 Spider naevi 
 Gynaecomastia 
 
 
 
 
2.RENAL  DYSFUNCTION 
 Acute reduction in urine output in type 1 HRS 
 Gradual decline of urine output in type 2 HRS.  
3.HEMODYNAMIC  ABNORMALITIES 
 Features of hyperdynamic circulation and reduced systemic vascular 
resistance. 
 Tachycardia 
 Low JVP 
 Wide pulse pressure 
 Low MAP 
LABORATORY FINDINGS 61 
 Elevated blood urea nitrogen  and  serum  creatinine 
 Hyponatremia  and  hyperkalemia 
 Elevated plasma renin  and  noradrenaline  activity 
 Low  plasma osmolality 
 Increased urine osmolality 
 Reduced urine sodium excretion 
 
 
 
 
MANAGEMENT OF HEPATORENAL   SYNDROME 
 Measures  to  prevent  variceal  bleeding 
 Administration  of  pentoxiphylline  for  alchoholic  hepatitis 
 
PREVENTION62 
 Cautious use of nephrotoxins. 
 Early  detection  and  management  of  spontaneous  bacterial  
peritonitis and other  infections 
 Avoiding conditions producing intravascular volume depletion. 
 Lactulose  administration,  
 Avoid large  volume paracentesis   without  replacing  adequate  
intravenous albumin 
 Diuretics  
 MEDICAL  MANAGEMENT 
INTRAVENOUS  ALBUMIN 
 Expansion of the volume of the plasma with albumin given 
intravenously.63Start with a dose 1g/kg/day to a maximum of 100g/day 
followed by 20-60g/day    
 
 
 
 
VASOPRESSORS 
 Vasopressin  
 Noradrenaline  
 Midodrine 
 Octreotide 
MECHANISM OF  ACTION 
 
 
 
 
 
 
 
 
 
 
 Addition of intravenous Albumin enhances the potency of 
vasoconstrictor drugs by increasing the effective arterial blood volume 
and cardiac function.64 
SUPPRESSION OF RAAS AND SNS 
INCREASED MEAN ARTERIAL 
PRESSURE 
VASOCONSTRICTION OF SPLANCHNIC  
ARTERIAL BED 
INCREASED   SYSTEMIC VASCULAR 
RETURN 
 
IMPROVES RENAL PERFUSION 
 
 
VASOPRESSIN ANALOGUES – TERLIPRESSIN,65,66,67 
 Terlipressin is the drug of choice. 
 It is a vasopressin  analogue with  affinity  to  V1  receptors in  
vascular smooth  muscles 
 The Acute Dialysis Quality Initiative (ADQI) work group   
recommends the combined use of vasoconstrictor drugs with intravenous 
albumin   as first  line  of  management  for   treatment for type 1 HRS.68 
BETTER  PREDICTORS  OF  RESPONSE69,70 
 Pretreatment  bilirubin less than 10 mg/dl 
 Increase in MAP more than 5mmHg at third day of therapy  
CONTRINDICATIONS OF  TERLIPRESSIN 
 Cardiovascularproblems 
 Peripheral vascular disease. 71 
 Cerebrovascular  incidents. 
 A multicentre randomised controlled trial compared the advantage 
of terlipressin and albumin to only  albumin in 46 patients with HRS.72. 
This showed improvement  in  renal function in the former group (43.5% 
versus 8.7% ) 
No advantage of survival in either group at three months. 
 
 
MIDODRINE73 
 Midodrine is a potent orally administered α1-adrenergic agonist. 
 Increases the circulating  blood  volume  by  splanchnic  
vasoconstriction  and  increasing  the  renal  perfusion 
 Titrated  to a MAP increase of 15 mm Hg 
OCTREOTIDE74,75 
 Somatostatin analog that inhibits endogenous vasodilator 
peptides. 
NOREPINEPHRINE76 
 Alpha 1 adrenergic agonist 
 Titrate to a MAP increase of at least 10 mm Hg 
 
 
 
 
 
 
 
 
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT  
 TIPS involves  the  insertion of an  transjugular  intrahepatic stent 
connecting  portal vein to the hepatic vein  that  shunts  the blood from  
portal  to systemic circulation.  
 This lowers portal venous pressure  and   decreases  venous  
pooling in  splanchnic  circulation  thus  increasing  the systemic venous 
return and supresses  the arterial under filling and the over activity of the 
RAAS and  SNS  and  renal  function 
CONTRAINDICATIONS 
 INR > 2 
 Bilirubin > 5mg/dl 
 CP score > 11 
 Cardiac and pulmonary disease. 
INDICATIONS 
 Diuretic-resistant ascites, a precursor to type 2 HRS.77 
 TIPS may be used as a bridge to transplantation for   the patients 
planned for surgery to improve the outcome. 
Overall survival following TIPS  
 81% at three months,  
 
 
 71% at six months,  
 48% at 12 months, 
 35% at 18 months.  
Recommendations from ADQI group 
 TIPS should not be used as the first line treatment modality for type 1 
HRS  
 
EXTRACORPOREAL SUPPORT SYSTEM  
 Lack of a definitive survival benefit and it is more expensive 
 Renal replacement therapy  
 Continuous veno veno  hemofiltration 
 Molecular adsorbent recirculating system 
 Prometheus 
RENAL REPLACEMENT THERAPY 
 Often  used  as  a  bridge  to  liver transplantation when  life  
threatening  complications of renal failure like  volume overload status 
metabolic acidosis, hyperkalaemia, and  uraemic symptoms present. 
INDICATIONS 
 Not responding to vasoconstrictor drugs  
 
 
 
ADVERSE EFFECTS 
 Hypotension  
 Infection  
 Coagulopathy 
 Renal  replacement  therapy  is  not  advisable  in  patients  with  
type  1  HRS  unless the  condition  is  reversible  or  there is plan  for  
transplantation.78 
 
VENOVENOUS HAEMOFILTRATION  
 Unstable patients  
 Raised intracranial pressure. 
 
MOLECULAR ADSORBENT RECIRCULATING SYSTEM 
(MARS) 
 The  dialysis  technique  is  modified  in  such  a  way  that  the  
albumin  bound  and  water  soluble  particles such  as  NO, TNF, 
cytokines  are  removed . 
RELIEF TRIAL 
 Compared MARS with standard therapy on patients with chronic 
liver failure..79 
 No improvement of overall survival and providing only temporary 
benefits. 
 
 
PROMETHEUS80 
Fractional  plasma  separation  and  removal  of  albumin  bound  
substances  with  hemodialysis. 
LIVER TRANSPLANTATION 
 Liver transplantation is the best treatment modality for the 
management of HRS. 
Iwatsuki et al. reported that liver transplantation in three cirrhotic 
patients with HRS led to improved liver and renal function within two 
weeks of operation.. 
TRANSPLANTATION WITH HRS 
 Three year survival rate  60% 
 Poor postoperative  outcome  with  increased mortality 
 Long  term  RRT in  postoperative  period.81 
TRANSPLANTATION WITHOUT HRS 
 3  year  survival  rate 70% to 80% 82 
 Better outcome. 
 The  3-year survival  rate  for  living  donor  liver  transplantation  
was 85.3% compared with 60.9% for orthotopic  liver  transplantation. 
 
 
 
OUTCOME  
 Recovery of renal function after transplantation is 58% - 94%83 
 Recovery of renal function fails to occur when 84 
 The time duration between the onset of HRS and liver 
transplantation≥ 4–6 weeks. 
 Dialysis for ≥ 8 weeks in  preoperative  period 
 Serum creatinine of ≥ 2mg/dL  
Combined liver and kidney transplantation is advantageous in such 
groups.85 
PROPHYLAXIS 
 Reduces  the  risk  of  developing  HRS 
 Combination  of  cefotoxime and albumin  has  a  reduced 
incidence to develop HRS  than  using  only  cefotoxime   
 Pentoxifylline, a phosphodiesterase inhibitor  has  advantageous 
effectsin  reduction   in  development  of  HRS 
  
 
 
RENAL RESISTIVE INDEX 
 RRI  is   a  Doppler  derived  parameter often  used as an indicator  
for  assessing the  renal  vascular  resistance. Importance  of  RRI  is  that  
even  in  presence  of  normal  glomerular filtration  rate  the  RRI  is  
elevated  thus  indicating  a  poorer  prognostic outcome 
 
 
Figure 23: Renal Color Doppler 
 Localisation  of  the  vessel  is  done  by  a  high  frequency  probe 
combined  together with  a  colour  Doppler. 
 The  RRI  is  usually  sampled  from  the  interlobar  and  arcuate  
arteries near  the  medullary  pyramids as  the  resistance  gradually  
increases  from  the  hilar  branches to  the  peripheral branches. 
 
 
 Measurements should be repeated in various parts of both kidneys 
(superior, median, and lower). Minimum of three reproducible 
waveforms has to be determined. 
FORMULA  FOR  RI  CALCULATION 
RI - (PSV– EDV/PSV) 
 The mean  of three   values  in  each kidney  is  preferentially  
taken  in  the end of  the  procedure. 
CUT OFF VALUES86 
 normal - 0.60 ± 0.01 (mean_SD) 
 upper  limit -0.7 
EXCEPTION 
 Children  less  than  1  year87 
 Healthy  elderly  adults 
PITFALLS IN RRI 
 Difficulty  in   obtaining  the  value   in  the  presence  of  
arrhythmic  disorders  like  AF. 
 Affected  by  stiffening  of  vasculature  and  fibrosis  of  
interstitium  and other  related  pathological  changes. 
 
 
 
ADVANTAGES 
        RRI is useful in the evaluation of 
 Renal artery stenosis 89,90 
 Chronic  rejection  of renal allograft 91 
 Progression  in  course  of  CKD 
 Obstructive  renal disease92 
 RRI  also  has  an  important  role  in  predicting  survival  outcome 
in critically ill patient  as  it  not  only  correlates  with  alteration  in  
intrarenal      perfusion  but  reflects the  hemodynamics  in  systemic  
circulation  thus leading  to  prognostic  clues  and  treatment  
modalities.93,94 
 This  application  of  RI  is  deployed in  the determination of  the  
degree  of  renal  vasoconstriction  in  advanced  cirrhosis  patients  and  
for  its  prognosis  and  treatment. 
  According to the study, increased RIs may even predict in earlier 
the progression of the liver disease   before overt changes develops. 
 
 
 
 
 
RRI AND CREATININE 
 Renal resistive index is better parameter than creatinine to predict 
 the development of HRS because 
 Decreased endogenous creatinine formation because of reduced 
synthesis by liver.  
 Low muscle mass from malnutrition 
 Drug related tubular secretion of creatinine 
 Fluctuations in serum creatinine in cirrhotic patients because of 
diuretic therapy and large volume paracentesis with volume 
expansion. 
 Underestimation of creatinine values due to its interactions with the 
bilirubin.95,96  
 Hence new renal biomarkers like cystatin and N GAL are 
advocated but they are very expensive and not available widely. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
 
 
 
 
MATERIALS AND METHODS 
SOURCE OF DATA: 
 Patients admitted in Institute of Internal Medicine, Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai-3 
diagnosed to have cirrhosis of liver, fulfilling the inclusion and exclusion 
criteria were included in the study group. 100 such patients were taken up 
for this study. 
STUDY DESIGN: 
 A hospital based observational study 
STUDY DURATION: 
 6 months: March 2015-August 2015 
INCLUSION CRITERIA: 
 Proven cases of cirrhosis  liver by clinical, laboratory and 
sonographic evidence with normal renal functions 
EXCLUSION CRITERIA: 
 Diabetic kidney  disease 
 GI Bleeding 
 Spontaneous bacterial  peritonitis 
 Overt  hepatorenal  syndrome 
 
 
DATA COLLECTION AND METHODS: 
 Data was collected in a pretested proforma from eligible patients. 
100 patients were selected on the basis of simple random sampling. They 
were subjected to detailed history taking and clinical examination. The 
following investigations were done. 
 Complete blood count 
 LFT 
 RFT with electrolytes 
  Coagulation profile 
 Chest X-ray 
 Electrocardiogram 
 Viral markers 
 USG of abdomen 
 Portal Doppler 
 Renal  Doppler 
RENAL DOPPLER 
 Patients who were enrolled in the study were subjected to 
sonographic evaluation of the liver and the kidneys and the Doppler 
ultrasound was done on each kidneys. All patients were made to fast for 
at least 6 hours prior to the examination. All examinations were done 
 
 
using   5-12 MHz transducer. Patients were made to lie in supine position, 
right lateral and left lateral position.  
 Abdominal aorta was identified and the ostium of right and left 
main renal arteries were identified and the corresponding PSV and EDV 
were taken. Then the PSV and EDV were taken from the renal arteries at 
the hilum, lobar, lobular and arcuate arteries. Then mean RI was 
calculated for each right and left kidney and finally mean of the two 
values was calculated as the RI by the formula  
RI - (PSV– EDV/PSV) 
RRI value of more than 0.7 was taken as the cut off 
STASTICAL METHODS APPLIED: 
 Data were analysed by SPSS software. Statistical significance was 
shown by the Chisquare test. Variables were considered to be significant 
if p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation & Results 
 
 
 
 
OBSERVATION AND RESULTS 
Table 1: AGE DISTRIBUTION 
Age Group (Years) Frequency Percentage 
10-20 2 2.0 
21-30 10 10.0 
31-40 20 20.0 
41-50 33 33.0 
51-60 23 23.0 
Above 60 12 12.0 
Total 100 100.0 
 
 Among 100 patients included in our study, most cases of cirrhosis 
(33 patients) occur in the age group of 41-50 (33.0%) years. 
 
 
 
 
 
 
 
 
 
 
 
 
Chart 1:  AGE DISTRIBUTION 
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Table 2: SEX DISTRIBUTION 
Sex Frequency Percentage 
MALE 88 88.0 
FEMALE 12 12.0 
TOTAL 100 100.0 
 
 Among 100 patients included in our study, 88 patients (88.0%) 
were males and 12 patients (12.0%) were females. 
 
Chart 2: SEX DISTRIBUTION 
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Table 3: ETIOLOGY 
 
 
 
 
 
 
 In our study, etiology of cirrhosis was alcohol related in 75 patients 
(75%), viral for 13 patients (13%), and other miscellaneous causes were 
present for 12 patients. (12%) 
Chart 3: ETIOLOGY 
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Frequency Percentage 
ALCHOHOL 75 75 
VIRAL 13 13 
OTHERS 12 12 
TOTAL 100 100 
 
 
Table 4: DISTRIBUTION OF ICTERUS 
 
Frequency Percentage 
Yes 83 83.0 
No 17 17.0 
Total 100 100.0 
 
 Out of 100 patients studied, 83 patients (83%) had icterus and 17 
patients   (17%) were anicteric. 
 
Chart 4: DISTRIBUTION OF ICTERUS 
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Table 5: DISTRIBUTION OF PEDAL EDEMA 
 
Frequency Percentage 
Yes 63 63.0 
No 37 37.0 
Total 100 100.0 
 
 Among 100 patients included in our study, 63 patients (63%) had 
pedal edema. 
 
Chart 5: DISTRIBUTION OF PEDAL EDEMA 
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Table 6: DISTRIBUTION OF ASCITES 
 
Frequency Percentage 
Yes 80 80.0 
No 20 20.0 
Total 100 100.0 
 
Among 100 patients included in our study, 80patients (80%) had ascites. 
 
Chart 6: DISTRIBUTION OF ASCITES 
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Table 7: DISTRIBUTION OF HEPATIC ENCEPHALOPATHY 
Grades Frequency Percentage 
Gr 1 21 21.0 
Gr 2 3 3.0 
None 76 76.0 
Total 100 100.0 
 
 In our study 21 patients (21%) had grade 1 hepatic encephalopathy, 
3 patients (3%) had grade 2 encephalopathy. 
 
Chart 7: DISTRIBUTION OF HEPATIC ENCEPHALOPATHY 
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Table 8: GRADING OF ASCITES 
 
Frequency Percentage 
ABSENT 20 20.0 
MILD-MODERATE 42 42.0 
SEVERE 38 38.0 
TOTAL 100 100.0 
 
 Out of 100 patients, ascites was absent in 20 patients (20%), mild 
to moderate ascites in 42 patients (42%), severe ascites in 38patients 
(38%). 
Chart 8: GRADING OF ASCITES 
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Table 9: PORTAL HYPERTENSION 
 
 
Frequency Percentage 
Yes 27 27.0 
No 73 73.0 
Total 100 100.0 
 
 In our study portal hypertension was seen in 73 patients (73%). 
 
 
Chart 10: PORTAL HYPERTENSION 
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TABLE 10: CTP SCORE 
 
 
Frequency Percentage 
A 12 12.0 
B 34 34.0 
C 54 54.0 
TOTAL 100 100.0 
 
 In our study, out of 100 patients, 12 patients (12%) were in class A, 
34 patients (34%) were in class B and 54 patients (54%) were in class 
C.Majority of patients were in class C. Child-Pugh class is an indicator of 
severity of liver disease. 
 
Chart 10: CTP SCORE 
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Table 11: MELD SCORE 
 
Age Category Frequency Percentage 
< 9 2 2.0 
10 - 19 63 63.0 
20 - 29 35 35.0 
TOTAL 100 100.0 
 
 Among 100 patients included in our study, below are the findings: 
 <9       - 2 patients (2%) 
 10 - 19 - 63 patients (63%) 
 20 - 29   - 35 patients (35%) 
 
Chart 11: MELD SCORE 
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Table 12.RESISTIVE INDEX 
 
 
Frequency Percentage 
<=0.7 29 29.0 
>0.7 71 71.0 
TOTAL 100 100.0 
 
 In our study resistive index was more than 0.7 for 71 patients 
(71%) and less than 0.7 for 29 patients (29%). 
 
Chart 12: RESISTIVE INDEX 
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Table 13: RESISTIVE INDEX AND GRADING OF ASCITES 
Category N Mean 
Std. 
Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
ABSENT 20 0.697 0.0213 0.00476 0.687 0.707 0.67 0.76 
MILD - 
MODERATE 
42 0.717 0.01762 0.00272 0.7112 0.7222 0.69 0.76 
 
SEVERE 
38 0.769 0.02133 0.00346 0.7617 0.7757 0.71 0.8 
Total 100 0.733 0.03534 0.00353 0.7255 0.7395 0.67 0.8 
 
 When the grading of  ascites was compared with the resistive index 
the resistive index was more with the patients having severe ascites and 
the p value (<0.0001) is significant. 
 
 
 
 
 
 
 
 
Chart 13:  RESISTIVE INDEX AND GRADING OF ASCITES 
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Table 14: RESISTIVE INDEX AND CTP SCORE 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% 
Confidence 
Interval for 
Mean Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
A 12 0.6958 0.02021 0.00583 0.683 0.7087 0.68 0.74 
B 34 0.7165 0.02347 0.00402 0.7083 0.7247 0.67 0.78 
C 54 0.7507 0.03313 0.00451 0.7417 0.7598 0.69 0.8 
Total 100 0.7325 0.03534 0.00353 0.7255 0.7395 0.67 0.8 
 
 
 On comparing the three groups A, B, C resistive index is higher in 
C group (p<0.001) than the other signifying that severity of liver disease 
is related to increased RI values. 
 
 
 
 
 
 
 
 
 
 
Chart 14: RESISTIVE INDEX AND CTP SCORE 
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Table 15: RESISTIVE INDEX AND MELD SCORE 
 
 
N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maximum 
Lower 
Bound 
Upper 
Bound 
<9 2 0.68 0 0 0.68 0.68 0.68 0.68 
10 - 20 63 0.7186 0.02873 0.00362 0.7113 0.7258 0.67 0.79 
20 - 29 35 0.7606 0.02828 0.00478 0.7509 0.7703 0.7 0.8 
Total 100 0.7325 0.03534 0.00353 0.7255 0.7395 0.67 0.8 
 
Among 100 patients included in our study, below are the patients’ 
findings about MELD: 
 0-9 have RI ranging from 0.68 to 0.68 
 10-29  have RI ranging from  0.67 to 0.79 
 20-29  have RI  values from 0.70 to 0.80 
 
 
 
 
 
 
 
 
Chart 15: RESISTIVE INDEX AND MELD SCORE 
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Table 16: CORRELATION BETWEEN PHT AND RI 
 
RELATIVE INDEX 
SCORE 
Total 
Chi 
square 
P value 
<=0.7 >0.7 
Portal 
hypertension 
No 
Count 22 5 27 
49.476 P<0.0001 
% within 
RELATIVE 
INDEX 
SCORE 
75.90% 7.00% 27.00% 
Yes 
Count 7 66 73 
% within 
RELATIVE 
INDEX 
SCORE 
24.10% 93.00% 73.00% 
Total 
Count 29 71 100 
% within 
RELATIVE 
INDEX 
SCORE 
100.00% 100.00% 100.00% 
 
 
 In patients with PHT 93% had RI more than 0.7 and 24.1% had 
<0.7 .In patients without PHT 7 % had had RI more than 0.7 and 75.9 
patients had more 0.7.This signifies that presence of portal hypertension 
increases the intrarenal resistance and hence leading to HRS. 
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Table 17: CORRELATION BETWEEN CTP AND RI 
 
RELATIVE INDEX 
SCORE 
Total 
 
Chi 
square 
 
P value 
<=0.7 >0.7 
CTP Score 
A 
Count 9 3 12 
 
 
16.507 
 
 
 
 
 
 
 
P<0.001 
 
 
 
 
 
% within 
RELATIVE 
INDEX 
SCORE 
31.00% 4.20% 12.00% 
B 
Count 11 23 34 
% within 
RELATIVE 
INDEX 
SCORE 
37.90% 32.40% 34.00% 
C 
Count 9 45 54 
% within 
RELATIVE 
INDEX 
SCORE 
31.00% 63.40% 54.00% 
Total 
Count 29 71 100 
% within 
RELATIVE 
INDEX 
SCORE 
100.00% 100.00% 100.00% 
 
 Patients under CTP A class had RI ranging from o.68 to 0.74, CTP 
B class had the range from 0.67 to 0.78 and CTP C had RI from 0.69 to 
0.80.So the value was higher among patients under group C indicating as 
the severity disease increases RI also increases. RI less than 0.7 was seen 
in 31% in CTP A , 37.9%  CTP B, 31%  CTP  and more than 0.7  seen in  
4.2 % in CTP A , 32.4% CTP B, 63.4%  CTP  C. 
 
 
 
Chart 17: CORRELATION BETWEEN CTP AND RI 
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Table 18: CORRELATION BETWEEN RI AND MELD 
 
 In our study RI values less than 0.7 was seen in 6.9%having score 
of 0-9, 86.2% having score of 10-19, 6.9% having 20-29. 
 RI values more than 0.7 was seen in 0%having score of 0-9, 53.5% 
having score of 10-19, 46.5% having 20-29. 
 
 
MELD 
RELATIVE INDEX 
SCORE 
Total 
 
CHI 
SQUARE 
 
P 
VALUE <=0.7 >0.7 
<9 
Count 2 0 2 
 
 
17.605 
 
 
 
 
 
 
 
P<0.001 
 
 
 
 
 
% within 
RELATIVE 
INDEX 
SCORE 
6.90% 0.00% 2.00% 
10 - 19 
Count 25 38 63 
% within 
RELATIVE 
INDEX 
SCORE 
86.20% 53.50% 63.00% 
20 - 29 
Count 2 33 35 
% within 
RELATIVE 
INDEX 
SCORE 
6.90% 46.50% 35.00% 
Total 
Count 29 71 100 
% within 
RELATIVE 
INDEX 
SCORE 
100.00% 100.00% 100.00% 
 
 
Chart 18: CORRELATION BETWEEN RI AND MELD 
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 There was a significant linear correlation between renal resistive 
index and MELD scoring as shown by the plot   
 
 
 
 
 
 
 
 
 
y = 0.0046x + 0.6489
R² = 0.3359
0.66
0.68
0.7
0.72
0.74
0.76
0.78
0.8
0.82
8 13 18 23 28
R
I
CORRELATION BETWEEN RI AND MELD
19
12
16
23
15
14
16
22
11
23
18
21
Pearson Correlation 0.578 
P value <0.001 
N 100 
 
 
There was no significant correlation between the RRI and serum 
creatinine values 
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Discussion 
 
 
 
 
DISCUSSION 
        Our study was conducted in patients with cirrhosis  liver to estimate 
the value    of  renal resistive index by Doppler ultrasound  Our study 
population included 100 patients who were diagnosed to have  cirrhosis 
of liver either by clinical examinations and investigations, or sonographic 
evidence.  
          Portal Doppler was done to assess portal hypertension. All 100 
patients were subjected to Doppler ultrasound and the value of renal 
resistive index was calculated. Analysis was made to correlate the value 
of RI in patients with absent, mild- moderate and severe ascites. 
Comparison with CTP scores and MELD scores were also done. 
  Following were the observations made from our study in cirrhotic 
patients 
AGE DISTRIBUTION: 
 Out of 100 patients, majority of cases were in the age group of 41 – 
50 years (33%)). This showed that cirrhosis is most commonly seen in 
middle age adults. 
 
 
 
 
SEX DISTRIBUTION 
 Out of 100 patients in this study, 88 patients (88%) were males and 
12 patients (12%) were females. Male to female ratio is 7:1. 
ETIOLOGY 
 Among 100 patients, Alcohol was the most common etiology in 75 
patients (75%), viral etiology in14 patients (14%) followed by other 
causes of cirrhosis in 11 patients (11%). 
CLINICAL SIGNS: 
 Out of 100 patients studied, 83 patients (83%) had icterus, 62 
patients (62%) had pedal edema,80 patients (80%) had ascites, grade I 
hepatic encephalopathy in 21 patients(21%), and  grade 2 encephalopathy  
in 3(3%) patients 
GRADING OF ASCITES 
 Out of 100 patients, ascites was absent in 20 patients (20%), mild 
to moderate ascites seen in 42(42%) patients, severe ascites seen in 
38(38%) patients. 
 
 
 
 
PORTAL HYPERTENSION 
 Out of 100 patients PHT was there in patients in 73(73%) patients 
and absent in 27(27%) patients.  
CHILD-PUGH CLASS: 
 In our study, out of 100 patients, 12 patients (12%) were in class A, 
34 patients (34%) were in class B and 54 patients (54%) were in class C. 
Majority of patients were in class C. Child-Pugh class is an indicator of 
the severity of liver disease.  
MELD  
 In our study according to MELD score<9    -  2  patients (2%)    10- 
19  -  63 patients(63%)    20-29   -  35 patients(35%). 
RESISTIVE INDEX 
 In our study the resistive index was more than 0.7 for 71 patients 
(71%) and less than 0.7 for 29 patients (29%) 
 
ASCITES AND RI 
  The value of RI in patients for whom there was no ascites was 
ranging from 0.67 to 0.76, mild to moderate ascites was 0.69 to 0.76 and 
for severe ascites was from 0.71 to 0.80. so the RI was significantly 
 
 
higher in patients with severe ascites. This was comparable to the study 
done by M.Gotzberger et al. 
PHT AND RI: 
 In patients with PHT 93% had RI more than 0.7 and 24.1% had < 
0.7. In patients without PHT 7 % had had RI more than 0.7 and 75.9% 
patients had more 0.7.This Signifies that presence of portal hypertension 
increases the intrarenal resistance and hence leading to HRS. 
CPC AND RI 
 Patients under CPC A class had RI ranging from o.68 to 0.74, CPC 
B class    had the range from 0.67 to 0.78 and CPC C had RI from 0.69 to 
0.80.so the value was higher among patients under group C indicating as 
the severity disease increases RI also increases.  
 RI less than 0.7 was seen in  31%   in CPC A ,  37.9%  in  CPC B,  
31% in CPC C and more than 0.7  seen in  4.2%  in CPC A , 32.4%  CPC 
B,     63.4%   in CP C C. 
MELD AND RI 
  Patients having a MELD scoring of 0-9 have RI ranging from 0.68 
to 0.68,10-29  have RI ranging from  0.67 to 0.79 and 20-29  have RI  
values from 0.70 to 0.80 
 
 
 In our study RI values less than 0.7 was seen in 6.9%having score 
of 0-9 86.2% having   score of 10-19, 6.9% having 20-29 and RI values 
more than 0.7 was seen in 0% having score of 0-9, 53.5% having   score 
of 10-19, 46.5% having 20-29. 
 There is a significant direct linear relationship between RI and 
MELD scores. 
RRI AND SERUM CREATININE 
 Patients having higher resitive index had normal creatinine 
suggesting that normal value of creatinine underestimates the actual 
scenario in cirrhotic patients. 
  
 
 
RENAL RESISTIVE INDEX AND CIRRHOSIS 
 Renal resistive index is higher in cirrhotic patients and among them 
it is significantly higher in patients with severe ascites.  
1.This is similar to the study conducted by M.Gotzberger et al, Kaiser et   
al, N.Landeur et al. 
“INTRARENAL RESISTANCE INDEX FOR ASSESSMENT OF 
EARLY RENAL DYSFUNCTION IN PATIENTS WITH 
CIRRHOSIS” which concluded that significant higher RI found in 
patients with cirrhosis with ascites 
2. There is a correlation between MELD and RI  as similar to the study 
conducted by Sameh Ahmed Abdel-bary et al 
“VALUE OF RENAL RESISTIVE INDEX IN HEPATITIS 
C VIRUS RELATED LIVER CIRRHOSIS.” which 
concluded that RI is strongly associated with liver cirrhosis severity as 
showed by Child Pugh, MELD scores. RI also had a prognostic value 
correlating with MELD score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
 
 
 
CONCLUSION 
 Cirrhosis liver is commonly seen patients in their 4th decade (41-
50) and more common in males than in females. 
 Alcohol consumption is the major risk factor in the development of 
disease with viral hepatitis as the second risk factor. 
 Icterus, pedal edema ascites were the predominant findings in the 
patients 
 Mild to moderate ascites was seen more commonly among the 
patients with ascites 
 PHT was seen in most of the patients 
 Majority of the patients were in CPC class C and having  MELD  
score between 10-19 
 Intra renal resistive index more than 0.7 in was seen in majority of 
patients with cirrhosis 
 The RI values were more higher in patients with severe ascites than 
patients with mild to moderate ascites and still lower inpatients 
with no ascites 
 There was no significant correlation between serum creatinine and 
the value of RI 
 Patients with PHT had increased RI than without PHT 
 The  RI values were significantly higher in CPC class C 
 
 
 Patients with MELD score between 20-29 had higher RI compared 
to patient with score of less than 9 and between 10-19.  
 Significant correlation was seen between the severity of liver 
disease and the renal resistive index as compared with CPC and 
MELD scoring system. 
 Serum creatinine was normal in patients having significant high 
RRI thus indicating that serum creatinine is a poor predictor of 
development of HRS and underestimates the renal dysfunction. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
 
 
 
SUMMARY 
 Development of hepatorenal syndrome in cirrhosis has so many 
clinical implications in the course of their disease as they carry a poor 
prognosis. Diagnosis of HRS needs a very high index of suspicion in 
cirrhotic patients. 
 As the prognosis of HRS is so devastating after the disease 
manifests with rise in serum creatinine and BUN all patients with 
cirrhosis liver should be screened for the presence of elevated renal 
resistive index by Doppler ultrasound of kidneys so that the onset of HRS 
can be prevented. 
 RI values are higher in cirrhotic patients and among them it was 
more in patients with ascites than patients without ascites. There is a 
significant correlation between the RI values and the severity of liver 
disease as compared with MELD and CPC scoring. 
 Screening of all cirrhotic patients especially with ascites and PHT 
to estimate the value of RRI by Doppler ultrasound is essentially  
important as the degree of intrarenal vasoconstriction can be predicted 
early before overt HRS develops and so preventive measures should be 
undertaken. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
 
 
 
 
BIBLIOGRAPHY 
 
1.Gines A , Escorsell A , Gines P et al. Incidence, predictivefactors, and 
prognosis of the hepatorenal syndrome incirrhosis with ascites . 
Gastroenterology 1993 ; 105 : 229 – 236 . 
2.Arroyo V, Fernandez J, Gin?s P: Pathogenesis and treatment of 
hepatorenal syndrome.  Semin Liver Dis  2008; 28:81-95 
3.Angeli P, Merkel C: Pathogenesis and management of hepatorenal 
syndrome in patients with cirrhosis.  J Hepatol  2008; 48:S93-103. 
4.Shusterman B, Mchedishvili G, Rosner MH: Outcomes for hepatorenal 
syndrome and acute kidney injury in patients undergoing liver 
transplantation: A single center experience.  Transplant 
Proc  2007; 39:1496-500. 
5. Arroyo and R. Bataller, “Historical notes on ascites in cirrhosis,” 
in Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, 
Diagnosis and Treatment, V. Arroyo, P. Ginès, J. Rodes, R. W. Schrier, 
and M. A. Malden, Eds., pp. 3–13, Blackwell Science, 1999 
6. Helvig and C. Schutz, “A liver and kidney syndrome: clinical, 
pathological and experimental studies,”The Journal of Surgery, 
Gynecology and Obstetrics, vol. 55, pp. 570–582, 1932. 
 
 
7.Hecker and S. Sherlock, “Electrolyte and circulatory changes in 
terminal liver failure,” The Lancet, vol. 268, no. 6953, pp. 1121–1125, 
1956 
8.Sheila Sherlock, James Dooley; Hepatic Cirrhosis; Diseases OfLiver 
And Biliary System; Blackwell Science publishers; 11th ed.;368-80. 
9.Friedman SE: Mechanisms of hepatic fibrogenesis.Gastroenterology 
134:1655, 2008. 
10.Lefkowitch JH: Morphology of alcoholic liver disease.  Clin Liver 
Dis  2005; 9:37-53. 
11.Mathurin P, Beuzin F, Louvet A, et al: Fibrosis progression occurs in a 
subgroup of heavy drinkers with typical histological features.  Alimen 
Pharm Ther  2007; 25:1047-54. 
12.Reinke LA, Lai EK, DuBose CM, McCay PB: Reactive free radical 
generation in vivo in heart and liver of ethanol-fed rats: Correlation with 
radical formation in vitro.  Proc Natl Acad Sci USA  1987; 84:9223-7. 
13.Hoek JB, Cahill A, Pastorino JG: Alcohol and mitochondria: A 
dysfunctional relationship.  Gastroenterology  2002; 122:2049-63 
14.French SW: The role of hypoxia in the pathogenesis of alcoholic liver 
disease.  Hepatol Res  2004; 29:69-74. 
 
 
15.Reeves HL, Friedman SL: Activation of hepatic stellate cells—a key 
issue in liver fibrosis.  Front Biosci  2002; 7:d808-26. 
16.Bruce R Bacon. Cirrhosis and Its Complications; Harrisons Principles 
of 
Internal Medicine; 18th ed.; 2592-602. 
17. Dan L. Longo ... [et (2012). Harrison's principles of internal 
medicine. (18th ed.). New York: McGraw-Hill. pp. Chapter 308. 
Cirrhosis and Its Complications.  
18.william, james (2005). Andrews' Diseases of the Skin: Clinical 
Dermatology. Saunders 
19 .Li CP, Lee FY, Hwang SJ et al. (1999). "Spider angiomas in patients 
with liver cirrhosis: role of alcoholism and impaired liver 
function". Scand. J. Gastroenterol. 34 (5): 520–3. 
20.van Thiel, DH; Gavaler, JS; Spero, JA; Egler, KM; Wright, C; 
Sanghvi, AT; Hasiba, U; Lewis, JH (Jan–Feb 1981). "Patterns of 
hypothalamic-pituitary-gonadal dysfunction in men with liver disease due 
to differing etiologies.". Hepatology (Baltimore, Md.) 1 (1): 39–46 
21. Slater, Joseph S. Esherick, Daniel S. Clark, Evan D. Current practice 
guidelines in primary care 2013. New York: McGraw-Hill Medical. 
pp. Chapter 3: Disease Management. 
 
 
22 .Tangerman, A; Meuwese-Arends, MT; Jansen, JB (Feb 19, 1994). 
"Cause and composition of foetor hepaticus.". Lancet343 (8895): 483 
23.Current medical diagnosis and treatment 2014. [S.l.]: Mcgraw-Hill. 
pp. Chapter 16. Liver, Biliary Tract, & Pancreas Disorders. 
24.Suurmond, D. (2009). Color Atlas and Synopsis of Clinical 
Dermatology: Common and Serious Diseases. McGraw-Hill. pp. Section 
33: Disorders of the nail apparatus. 
25.Ellis G, Goldberg DM, Spooner RJ, Ward AM, et al. Serum enzyme 
tests in diseases of the liver and biliary tree. Am J ClinPathol 1978; 
70:248. 
26.Qamar AA, Grace ND, Groszmann RJ, et al. Incidence,prevalence, 
and clinical significance of abnormal hematologic indices in compensated 
cirrhosis. Clin Gastroenterol Hepatol 2009;7:689. 
27.Di Lelio A, Cestari C, Lomazzi A, Beretta L, et al. Cirrhosis:diagnosis 
with sonographic study of the liver surface. Radiology1989; 172:389. 
28.Sanford NL, Walsh P, Matis C, et al. Is ultrasonographyuseful in the 
assessment of diffuse parenchymal liver diseaseGastroenterology 1985; 
89:186. 
 
 
29.Foucher J, Chanteloup E, Vergniol J et al. (2006). "Diagnosis of 
cirrhosis by transient elastography (FibroScan): a prospective 
study". Gut 55 (3): 403–8.29 
30.Bravo AA, Sheth SG, Chopra S, et al. Liver biopsy. N Engl JMed 
2001; 344:495. 
31.Cholongitas, E; Papatheodoridis, GV; Vangeli, M; Terreni, N; Patch, 
D; Burroughs, AK (Dec 2005). "Systematic review: The model for end-
stage liver disease--should it replace Child-Pugh's classification for 
assessing prognosis in cirrhosis?". Alimentary pharmacology & 
therapeutics 22 (11-12): 1079–89. 
32 .Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, 
Kosberg CL, D'Amico G, Dickson ER, Kim WR (2001). "A model to 
predict survival in patients with end-stage liver 
disease". Hepatology 33 (2): 464–70. 
33.Kamath PS, Kim WR (March 2007). "The model for end-stage liver 
disease (MELD)". Hepatology 45 (3): 
 34.Wiesner et al. Model for end-stage liver disease (MELD) and 
allocation of donor livers. Gastroenterology (2003) vol. 124 (1) pp. 91-6 
 
 
35.Escorsell A, Gines A, Llach J, et al: Increased intra-abdominal 
pressure increases pressure, volume, and wall tension in esophageal 
varices.  Hepatology  2002; 36:936-40. 
36 Bustamante J, Rimola A, Ventura PJ, et al: Prognostic significance of 
hepatic encephalopathy in patients with cirrhosis.  J 
Hepatol  1999; 30:890-5. 
37 Angeli P, Merkel C: Pathogenesis and management of hepatorenal 
syndrome in patients with cirrhosis.  J Hepatol  2008; 48:S93-103. 
38 M. H. Koppel, J. W. Coburn, M. M. Mims, H. Goldstein, J. D. Boyle, 
and M. E. Rubini, “Transplantation of cadaveric kidneys from patients 
with hepatorenal syndrome. Evidence for the functionalnature of renal 
failure in advanced liver disease,” The New England Journal of Medicine, 
vol. 280, no. 25, pp. 1367–1371, 1969. 
39.F. Salerno, A. Gerbes, P. Ginès, F. Wong, and V. Arroyo, “Diagnosis, 
prevention and treatment of hepatorenal syndrome in cirrhosis,” Gut, vol. 
56, no. 9, pp. 1310–1318, 2007. 
40.The hepatorenal syndrome,” Medical Clinics of North America, vol. 
92, no. 4, pp. 813–837, 2008 
 
 
41 V. Arroyo, P. Ginès, A. L. Gerbes et al., “Definition and diagnostic 
criteria of refractory ascites and hepatorenal syndrome in 
cirrhosis,” Hepatology, vol. 23, no. 1, pp. 164–176, 1996 
42.(Salerno F, Gerbes A, Gin?s P, et al. Diagnosis, prevention and 
treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310-8). 
43.F. Salerno, M. Cazzaniga, M. Merli et al., “Diagnosis, treatment and 
survival of patients with hepatorenal syndrome: a survey on daily medical 
practice,” Journal of Hepatology, vol. 55, no. 6, pp. 1241–1248, 2011. 
44.P. Ginès, M. Guevara, V. Arroyo, and J. Rodés, “Hepatorenal 
syndrome,” The Lancet, vol. 362, no. 9398, pp. 1819–1827, 2003 
45.K. Moore, “Renal failure in acute liver failure,” European Journal of 
Gastroenterology and Hepatology, vol. 11, no. 9, pp. 967–975, 1999. 
46. S. Verma, K. Ajudia, M. Mendler, and A. Redeker, “Prevalence of 
septic events, type 1 hepatorenal syndrome, and mortality in severe 
alcoholic hepatitis and utility of discriminant function and MELD score 
in predicting these adverse events,” Digestive Diseases and Sciences, vol. 
51, no. 9, pp. 1637–1643, 2006.  
47.A. Follo, J. M. Llovet, M. Navasa et al., “Renal impairment after 
spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, 
 
 
predictive factors and prognosis,” Hepatology, vol. 20, no. 6, pp. 1495–
1509  
48.M. Navasa, A. Follo, X. Filella et al., “Tumor necrosis factor and 
interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship 
with the development of renal impairment and mortality,”Hepatology, 
vol. 27, no. 5, pp. 1227–1232, 1998 
49.P. Gines, L. Tito, V. Arroyo et al., “Randomized comparative study of 
therapeutic paracentesis with and without intravenous albumin in 
cirrhosis,” Gastroenterology, vol. 94, no. 6, pp. 1493–1502, 1988. 
50.A. Cárdenas, P. Ginès, J. Uriz et al., “Renal failure after upper 
gastrointestinal bleeding in cirrhosis: Incidence, clinical course, 
predictive factors, and short-term prognosis,” Hepatology, vol. 34, no. 4 
I, pp. 671–676, 2001. 
51. A. Bomzon, S. Holt, and K. Moore, “Bile acids, oxidative stress, and 
renal function in biliary obstruction,” Seminars in Nephrology, vol. 17, 
no. 6, pp. 549–562, 1997. 
52.S. Montoliu, B. Balleste, R. Planas, et al., “Incidence and prognosis of 
different types of functional renal failure in cirrhotic patients with 
ascites,” Clinical Gastroenterology and Hepatology, vol. 8, pp. 616–622, 
2010.  
 
 
53. J. F. Platt, J. H. Ellis, J. M. Rubin, R. M. Merion, and M. R. Lucey, 
“Renal duplex Doppler ultrasonography: a noninvasive predictor of 
kidney dysfunction and hepatorenal failure in liver disease,”Hepatology, 
vol. 20, no. 2, pp. 362–369, 1994. 
54 .M. Epstein, D. P. Berk, N. K. Hollenberg et al., “Renal failure in the 
patient with cirrhosis. The role of active vasoconstriction,” The American 
Journal of Medicine, vol. 49, no. 2, pp. 175–185, 1970.  
55.Bolognesi M, Sacerdoti D, Piva A, et al: Carbon monoxide-mediated 
activation of large conductance calcium-activated potassium channel 
contributes to mesenteric vasodilation in cirrhotic rats.  J Pharmacol Exp 
Ther  2007; 321:187-94. 
56.Fernandez-Seara J, Prieto J, Quiroga J, et al: Systemic and regional 
hemodynamics in patients with liver cirrhosis and ascites with and 
without functional renal failure.  Gastroenterology  1989; 97:1304-12. 
57. Epstein M. Renal prostaglandins and the control of renal function in 
liver disease. Am J Med. 1986;80:46–6 
58. Guarner C, Colina I, Guarner F, et al. Renal prostaglandins in 
cirrhosis of the liver. Clin Sci (Lond) 1986;70:477–84.  
 
 
59. Laffi G, La Villa G, Pinzani M, et al. Altered renal and platelet 
arachidonic acid metabolism in 
cirrhosis. Gastroenterology. 1986;90:274–82.  
60. E. T. Schroeder, R. H. Eich, H. Smulyan, A. B. Gould, and G. J. 
Gabuzda, “Plasma renin level in hepatic cirrhosis. Relation to functional 
renal failure,” The American Journal of Medicine, vol. 49, no. 2, pp. 186–
191, 1970 
61. A. Gines, A. Escorsell, P. Gines et al., “Incidence, predictive factors, 
and prognosis of the hepatorenal syndrome in cirrhosis with 
ascites,” Gastroenterology, vol. 105, no. 1, pp. 229–236, 1993. 
62.Salerno F, Gerbes A, Gin?s P, et al: Diagnosis, prevention and 
treatment of hepatorenal syndrome in cirrhosis.  Gut  2007; 56:1310-18. 
63.Guevara M, Ginès P, Fernández-Esparrach G et al. (1998). 
"Reversibility of hepatorenal syndrome by prolonged administration of 
ornipressin and plasma volume expansion". Hepatology 27 (1): 35–41. 
64.Halimi C, Bonnard P, Bernard B, et al: Effect of terlipressin 
(Glypressin) on hepatorenal syndrome in cirrhotic patients: Results of a 
multicentre pilot study.  Eur J Gastroenterol Hepatol  2002; 14:153-8.  
 
 
 
65.Duhamel C, Mauillon J, Berkelmans J, et al: Hepatorenal syndrome in 
cirrhotic patients: Terlipressin is a safe and efficient treatment; 
propranolol and digitalic treatments: Precipitating and preventing 
factors?.  Am J Gastroenterol  2000; 95:2984-5.  
66.Colle I, Durand F, Pessione F, et al: Clinical course, predictive factors 
and prognosos in patients with cirrhosis and type-1 hepatorenal syndrome 
treated with terlipressin: A retrospective analysis.  J Gastroenterol 
Hepatol  2002; 17:882-7. 
67. Danalioglu A, Cakaloglu Y, Karaca C, et al: Terlipressin and albumin 
combination treatment in hepatorenal 
syndrome.  Hepatogastroenterology  2003; 50(Suppl 2):ccciii-v. 
68 .M. K. Nadim, J. A. Kellum, A. Davenport et al., “Hepatorenal 
syndrome: the 8 th international consensus conference of the Acute 
Dialysis Quality Initiative (ADQI) Group,” Critical Care, vol. 16, no. 1, 
article R23, 2012. 
69.R. Moreau and D. Lebrec, “The use of vasoconstrictors in patients 
with cirrhosis: type 1 HRS and beyond,” Hepatology, vol. 43, no. 3, pp. 
385–394, 2006. 
70.T. D. Boyer, A. J. Sanyal, G. Garcia-Tsao et al., “Predictors of 
response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 
 
 
1: relationship of serum creatinine to hemodynamics,” Journal of 
Hepatology, vol. 55, no. 2, pp. 315–321, 2011 
71.P. Ginès, P. Angeli, K. Lenz et al., “EASL clinical practice guidelines 
on the management of ascites, spontaneous bacterial peritonitis, and 
hepatorenal syndrome in cirrhosis,” Journal of Hepatology, vol. 53, no. 3, 
pp. 397–417, 2010 
72 .M. Martín-Llahí, M.-N. Pépin, M. Guevara et al., “Terlipressin and 
albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: 
a ran domized study,” Gastroenterology, vol. 134, no. 5, pp. 1352–1359, 
2008 
73.Angeli P, Volpin R, Gerunda G, et al: Reversal of type 1 hepatorenal 
syndrome with the administration of midodrine and 
octreotide.  Hepatology  1999; 29:1690- 
74. Panteris V, Karamanolis DG: The puzzle of somatostatin: Action, 
receptors, analogues and 
therapy.  Hepatogastroenterology  2005; 52:1771-81. 
75. Esrailian E, Pantangco ER, Kyulo NL, et al: Octreotide/Midodrine 
therapy significantly improves renal function and 30-day survival in 
patients with type 1 hepatorenal syndrome.  Dig Dis Sci  2007; 52:742-8. 
 
 
76.Alessandria C, Ottobrelli A, Debernardi-Venon W, et al: Noradrenalin 
vs. terlipressin in patients with hepatorenal syndrome: A prospective, 
randomized, unblinded, pilot study.  J Hepatol  2007; 47:499-505. 
77. Boyer TD: Transjugular intrahepatic portosystemic shunt in the 
management of complications of portal hypertension.  Curr 
Gastroenterol Rep  2008; 10:30-5 
78. M. K. Nadim, J. A. Kellum, A. Davenport et al., “Hepatorenal 
syndrome: the 8 th international consensus conference of the Acute 
Dialysis Quality Initiative (ADQI) Group,” Critical Care, vol. 16, no. 1, 
article R23, 2012.  
79. R. Bañares, F. Nevens, F. S. Larsen et al., “Extracorporeal albumin 
dialysis with the molecular adsorbent recirculating system in acute-on-
chronic liver failure: the RELIEF trial,” Hepatology, vol. 57, no. 3, pp. 
1153–1162, 2013 
80.K. Rifai, T. Ernst, U. Kretschmer et al., “The Prometheus device for 
extracorporeal support of combined liver and renal failure,” Blood 
Purification, vol. 23, no. 4, pp. 298–302, 2005. 
81.T. A. Gonwa, G. B. Klintmalm, M. Levy, L. S. Jennings, R. M. 
Goldstein, and B. S. Husberg, “Impact of pretransplant renal function on 
 
 
survival after liver transplantation,” Transplantation, vol. 59, no. 3, pp. 
361–365, 1995.  
82.Nair S, Verma S, Tuluvath PJ: Pretransplant renal function predicts 
survival in patients undergoing orthotopic liver 
transplantation.  Hepatology  2002; 35:1179- 
83.X. Xu, Q. Ling, M. Zhang et al., “Outcome of patients with 
hepatorenal syndrome type 1 after liver transplantation: Hangzhou 
experience,” Transplantation, vol. 87, no. 10, pp. 1514–1519, 2009 
84.J. D. Eason, T. A. Gonwa, C. L. Davis, R. S. Sung, D. Gerber, and R. 
D. Bloom, “Proceedings of consensus conference on simultaneous liver 
kidney transplantation (SLK),” The American Journal of Transplantation, 
vol. 8, no. 11, pp. 2243–2251, 2008 
85. M. K. Nadim, J. A. Kellum, A. Davenport et al., “Hepatorenal 
syndrome: the 8 th international consensus conference of the Acute 
Dialysis Quality Initiative (ADQI) Group,” Critical Care, vol. 16, no. 1, 
article R23, 2012 
86.Tublin ME, Bude RO, Platt JF. The resistive index in renal 
Dopplersonography: where do we stand? AJR Am J Roentgenol 2003; 
180:885– 
892 
 
 
87.Bude RO, DiPietro MA, Platt JF, Rubin JM, Miesowicz S, Lundquist 
C.Age dependency of the renal resistive index in healthy 
children.Radiology 1992; 184:469–473. 
88. Kaiser C, Go¨tzberger M, Landauer N, Dieterle C, Heldwein 
W,Schiemann U. Age dependency of intrarenal resistance index (RI) 
inhealthy adults and patients with fatty liver disease. Eur J Med Res 
2007;12:191–195. 
89.Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, 
et al.Use of Doppler ultrasonography to predict the outcome of therapy 
forrenal-artery stenosis. N Engl J Med 2001; 344:410–417. 
90.Crutchley TA, Pearce JD, Craven TE, Stafford JM, Edwards MS, 
Hansen KJ. Clinical utility of the resistive index in atherosclerotic 
renovasculardisease. J Vasc Surg 2009; 49:148–155. 
91.Radermacher J, Mengel M, Ellis S, Stuht S, Hiss M, Schwarz A, et al. 
Therenal arterial resistance index and renal allograft survival. N Engl J 
Med 2003; 349:115–124. 
92.Radermacher J, Ellis S, Haller H. Renal resistance index and 
progression 
of renal disease. Hypertension 2002; 39:699–703. 
93.Hashimoto J, Ito S. Central pulse pressure and aortic stiffness 
determine 
 
 
renal hemodynamics: pathophysiological implication for 
microalbuminuria 
in hypertension. Hypertension 2011; 58:839–846. 
94.Pearce JD, Craven TE, Edwards MS, Corriere MA, Crutchley 
TA,Fleming SH, et al. Associations between renal duplex parametersand 
adverse cardiovascular events in the elderly: a prospective cohortstudy. 
Am J Kidney Dis 2010; 55:281–290. 
95.M. A. Papadakis and A. I. Arieff, “Unpredictability of clinical 
evaluation of renal function in cirrhosis. Prospective study,” The 
American Journal of Medicine, vol. 82, no. 5, pp. 945–952, 1987.   
96.L. Caregaro, F. Menon, P. Angeli et al., “Limitations of serum 
creatinine level and creatini.ne clearance as filtration markers in 
cirrhosis,” Archives of Internal Medicine, vol. 154, no. 2, pp. 201–205, 
1994. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexures 
 
 
 
 
 
PROFORMA 
PATIENT DETAILS: 
Name:     Age:   Sex:   
IP No. : 
 
ON ADMISSION: 
Main Complaints :  
 Jaundice    
 Abdominal Distension           
 Pedal Oedema 
 Reduced Urine Output 
 Breathlessness 
 Orthopnoea/Pnd 
 Haemetemesis 
 Melena 
 Seizures 
 Altered Sensorium 
 Altered Sleep Pattern 
 Chest Pain 
 Abdominal  Pain 
 Fever 
 Constipation           
 Intake Of Any Drugs 
 
 
 
 
SIGNIFICANT PAST HISTORY: 
 Ischemic heart disease 
 Hypertension 
 Diabetes 
 Pulmonary TB 
 Bronchial asthma 
 Blood transfusion 
 Jaundice 
 
PERSONAL HISTORY: 
 Smoking 
 Alcohol 
 
GENERAL EXAMINATION: 
 Built 
 Nourishment 
 Height 
 Weight 
 Pallor 
 Icterus 
 Clubbing 
 Cyanosis 
 Pedal edema 
 Lymphadenopathy 
 Jugular venous pulse 
 Signs of Liver cell failure 
 
 
 
 
VITAL SIGNS: 
 PR- 
 BP- 
 RR 
 
SYSTEMIC EXAMINATION: 
 
 PER ABDOMEN: 
 CARDIOVASCULAR SYSTEM: 
 RESPIRATORY SYSTEM: 
 CENTRAL NERVOUS SYSTEM 
INVESTIGATIONS : 
 Hemogram  
 Renal Function Test  
 Liver  Function  Test 
 BT/CT/PT/INR  
 Blood Grouping  
 ECG  
 CXR  
 USG Abdomen and  pelvis 
 Portal Doppler 
 Renal Doppler 
 
 
 
 
 
 
INFORMATION SHEET 
 
 
We are conducting a study on “THE ROLE OF RENAL 
RESISTIVE INDEX IN ASSESSING THE EARLY RENAL 
DYSFUNCTION OF CIRRHOSIS” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your 
cooperation may be valuable to us. 
The purpose of this study is to  measure  the intrarenal  resistive 
index in patients with liver cirrhosis, to estimate  the renal  
vasoconstriction before overt hepatorenal  syndrome   develops in 
cirrhotic patients  with  and without  ascites .and to  compare  the  
resistive  index  with  MELD and  Child Pugh scoring  system with the 
following factors Age, Sex, Presenting Complaints, Etiology of cirrhosis, 
Clinical findings, USG abdomen, Portal Doppler and Renal Doppler. We 
are selecting certain cases and if you are found eligible, we may be doing 
Renal Doppler Ultrasound your blood samples to do certain tests which in 
any way do not affect your final report or management. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. The results of the special study may be intimated to you at the 
end of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
 
 
Signature of Investigator     Signature of Participant 
 
Date : 
Place : 
 
 
 
PATIENT CONSENT FORM 
 
Study Detail : “THE  ROLE  OF  RENAL  RESISTIVE  
INDEX  IN ASSESSING THE EARLY RENAL  
DYSFUNCTION OF  CIRRHOSIS” 
 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have 
been answered to my complete satisfaction.  
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected.  
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from this study.  
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
I hereby consent to participate in this study 
 
 
 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests.  
 
 
 
Signature/thumb impression 
Patient’s Name and Address:
Signature of Investigator 
Study Investigator’s Name: 
Dr. NIVETHITHA KARTHIKA    
 
 
ஆராய்சச்ி ஒப்புதல் படிவம் 
 
ஆராய்சச்ியின்தலலப்பு கல்லீரல் இலைநார ்வளரச்ச்ியில் ஏற்படும் சிறுநீரக 
பாதிப்பிலன ஆரம்ப நிலலயில்க ண்டறிய சிறுநீரகத்தில் உள்ள 
சிறுதமணிகளின் குருதி பாய்வு எதிரப்்பின் மூலம் கண்டறிதல். 
 
ஆராய்சச்ிசசய்பவரின்சபயர ்:  நிவவதிதா காரத்்திகா ல. 
ஆராய்சச்ிலமயம்: ராஜீவ்காந்தி அரசுசபாது மருத்துவமலன   
   சசன்லன – 600003 
 
                    எனும் நான்  எனக்கு சகாடுதத்ுள்ள தகவல் தாலள படித்து புரிந்து 
சகாண்வடன். நான் பதிசனட்டு வயலத கடந்துள்ளதால் என்னுலடய 
சுயநிலனவுடனும் முை சுகந்திரதுடனும்  இந்த ஆராய்சச்ியில் என்லன 
வசரத்்துக் சகாள்ள சம்மதிக்கிவறன். 
 
1. நான் எனக்கு அளிக்கப்பட்ட ஒப்புதல் படிவத்லதயும் தகவல்கலளயும் 
படித்து புரிந்து சகாண்வடன். 
2. ஒப்புதல் படிவத்தில் உள்ள தகவல்கள் எனக்கு விளக்கிக் கூறப்பட்டன 
3. ஆய்வின் தன்லம பற்றி எனக்கு விளக்கப்பட்டது 
4. என்னுலடய உரிலமகலளயும்  சபாறுப்புகலளயும் ஆராய்சச்ியாளர ்
விளக்கிக்கூறினார.் 
5. நான் இதுவலர எடுதத்ுள்ள / எடுதத்ு சகாண்டிருக்கும் அலணத்து 
விதமான சிகிசல்ச முலறகலளயும் ஆராய்சச்ியாளரிடம் 
கூறியுள்வளன். 
6. இந்த ஆராய்சச்ியினால் ஏற்படும் தீலமகள் பற்றிவிளக்கப்பட்டன. 
 
 
ஆராய்சச்ியாளர ்லகசயாப்பம்                                பங்வகற்பாளரின் லகசயாப்பம்   
 
வததி 
 இடம் 
 
 
 
 
 
 
 
ஆராய்சச்ியில் பங்கேற்பவரே்ான தேவல்அறிே்கே 
 
ஆராய்சச்ியின் தகலப்பு கல்லீரல் இலை நார ் வளரச்ச்ியில் ஏற்படும் 
சிறுநீரக பாதிப்பிலன ஆரம்பநிலலயில் கண்டறிய சிறுநீரகத்தில் உள்ள 
சிறுதமணிகளின் குருதி பாய்வு எதிரப்்பின் மூலம்கண்டறிதல். 
பங்கு சகாள்வரின் சபயர ்: 
ஆராய்சச்ி சசய்பவரின் சபயர ்:  நிவவதிதா காரத்்திகா ல. 
இடம் : ராஜீவ்காந்தி அரசு சபாதுமருத்துவமலன, சசன்லன – 600003 
இந்த ஆராய்சச்ி / ஆய்வு / சசய்முலற / வசாதலனயில் தாங்கள் பங்வகற்க 
அலைக்கிவறாம். இந்த தகவல் அறிக்லகயில் கூறப்பட்டிருக்கும் தகவல்கள் 
தாங்கள் இந்த ஆராய்சச்ியில் பங்வகற்வகலமா வவண்டாமா என்பலத முடிவு 
சசய்ய உதவியாக இருக்கும். இந்த படிவதத்ில் உள்ள தகவல்கள் பற்றி உள்ள 
சந்வதகங்கலள நீங்கள் தயங்காமல் வகட்கலாம். 
இந்த ஆய்வின் கநாே்ேம்என்ன? 
 கல்லீரல் இலைநார ் வளரச்ச்ியில் ஏற்படும் சிறுநீரக பாதிப்பிலன 
ஆரம்பநிலலயில் கண்டறிய சிறுநீரகத்தில் உள்ள சிறுதமணிகளின் 
குருதிபாய்வு எதிரப்்பின் மூலம் கண்டறிதல்.. 
ஆய்வுமுகறேள் : 
 விரிவான வநாய்க்குறிப்புகளும் மருதத்ுவ பரிவசாதலனகளும் 
சசய்யப்படும்.வநாயாளிகள், அவரக்ள் சம்மதத்திற்கு பின் குருதிச ் சீரதத்ில் 
வகாலிசனஸ்சடவரஸ் எனும் என்லசம்மின் அளவு கணக்கிடப்படும். 
ஆய்வினால் மே்ேளுே்கு ஏற்படும் நன்கமேள் : 
 இந்த ஆய்வின் முடிவில் கிலடக்கும் தகவல்கள் சமுதாயதிற்கு 
பயனுள்ளதாகவும், எதிரக்ாலத்தில் வநாயாளிகளுக்கு மருதத்ுவ தீரவ்ாகவும் 
அலமயும். 
தங்ேளிடமிருந்து பபறப்படும் தேவல்ேளின் நம்பிேத்தன்கம :  
தங்களிடமிருந்து சபறப்படும் தகவல்கள் பாதுகாக்கப்படுவதற்கான முழு 
உரிமையும் தங்களுக்கு உண்டு. 
 
ஆராய்சச்ியாளர ்லகசயாப்பம்                               பங்வகற்பாளரின் லகசயாப்பம்   
 
வததி 
 இடம் 
 
 
THE ROLE OF RENAL RESISTIVE INDEX IN ASSESSING THE 
EARLY RENAL DYSFUNCTION OF CIRRHOSIS 
MASTER CHART 
S.no Age Sex IP no 
Alchohol 
intake 
Icterus 
 Pedal 
edema 
Ascites 
Hepatic 
encephalopathy 
Blood 
urea 
creatinine 
Serum 
bilurubin 
PT/ 
INR 
Serum 
albumin 
Viral 
markers 
Free  
fluid                   
in USG 
Portal 
hypertension 
CTP 
score 
MELD 
Resistive 
Index 
1 45 M 83609 +
 
+
 
+
 
+
 
none 32 0.6 6.5 1.6 2.4 Neg Severe + C 19 0.76 
2 56 M 88766  +
 
- + + none 21 0.3 2.3 1.2 3.1 Neg Absent _ B 12 0.69 
3 34 M 72600  +
 
+
 
- - none 17 1.1 4.6 1.3 3.5 Neg Absent - A 16 0.7 
4 54 M 67869  +
 
+
 
+ + Gr 1  37 0.7 8.5 2.1 1.9 Neg Severe + C 23 0.79 
5 48 F 76788 - +
 
+ + none 21 0.4 3.2 1.4 2.4 HbsAg Moderate + C 15 0.74 
6 39 M 69350  +
 
- - - none 27 0.8 2.9 1.4 2.9 Neg Absent - A 14 0.69 
7 65 M 86662  +
 
+
 
- - none 30 0.6 3.7 1.5 3.4 Neg Mild - B 16 0.71 
8 40 M 75738  +
 
+
 
+ + Gr 2 36 0.8 7.8 2.0 2.1 Neg Severe + C 22 0.75 
9 64 M 78205 - - - - none 32 0.6 3.2 1.0 2.9 HCV Mild - B 11 0.71 
10 41 M 92335  +
 
+
 
+ + Gr 1  28 0.7 14.2 1.8 2.2 Neg Severe + C 23 0.79 
11 48 M 91741  +
 
+
 
+ + Gr 1  27 0.8 6.4 1.5 1.6 Neg Moderate + C 18 0.7 
12 28 F 69898 - - + + none 34 0.6 2.3 2.6 2.6 Neg Severe + B 21 0.74 
13 53 M 73855  +
 
- - + none 40 0.3 2.8 1.3 2.8 Neg Mild - B 13 0.69 
14 56 M 72852  +
 
+
 
- + none 29 0.5 4.3 1.3 3.4 Neg Moderate + B 15 0.72 
15 44 M 84184 - +
 
+ + Gr 2 37 1.2 9.3 2.3 2.4 HbsAg Severe + C 26 0.77 
16 32 M 63656 +
 
+
 
- + none 34 0.7 8.4 1.4 3.5 Neg Mild - B 19 0.69 
17 46 M 70981 +
 
+
 
+
 
+
 
Gr 1  29 0.6 6.4 1 3 Neg Moderate + C 14 0.7 
18 49 M 83723 +
 
+
 
- + none 20 0.4 4.5 2.1 3.4 Neg Moderate + B 21 0.73 
19 34 M 67428 - - - - none 18 0.5 1.8 0.9 3.5 Neg Absent - A 9 0.68 
20 57 M 90660 +
 
+
 
+ + Gr 1  23 0.7 10.3 1.2 2.1 Neg Severe + C 17 0.76 
21 70 M 88579 - +
 
+
 
+
 
none 34 0.4 7.8 1.4 2.6 Neg Moderate + B 18 0.72 
22 69 M 74582 +
 
+
 
+ + Gr 1  38 0.4 15.4 2 3 neg Severe + C 25 0.78 
23 24 F 72137 - +
 
+ + none 40 0.7 4.6 1.4 3.6 Neg Severe + B 16 0.76 
 
 
24 30 M 70300 +
 
+
 
+ + none 34 0.8 6.5 2.3 2.3 neg Severe + C 23 0.79 
25 35 M 64728 - +
 
- + none 32 0.6 5.4 1.4 2.6 neg Moderate - C 17 0.69 
26 43 M 62329 +
 
+
 
+ + none 19 0.3 6.2 1.6 3.6 Neg Moderate + B 19 0.72 
27 55 M 78748 +
 
- - + none 32 0.6 4.3 1.4 2.8 neg Absent - B 16 0.7 
28 57 M 75447 +
 
+
 
+ + none 26 0.4 7.5 1.4 2.4 neg Mild + B 18 0.72 
29 19 M 90475 +
 
+
 
+ + Gr 1  18 1 10.6 1.9 3 neg Severe + C 23 0.76 
30 39 M 92818 +
 
+
 
- - none 26 0.6 4.3 1.1 2.8 neg Absent + B 13 0.7 
31 37 M 76862 +
 
+
 
- + none 32 0.6 6.4 1.4 2.8 neg Moderate + C 17 0.72 
32 40 M 65552 +
 
+
 
+ + none 40 0.6 10.8 2.1 2.1 HbsAg Severe + C 24 0.76 
33 59 F 79158 - +
 
+ + none 27 0.6 9.6 1.8 2.4 neg Severe + C 22 0.79 
34 62 F 86485 +
 
- - - none 14 0.3 2.5 0.9 3.5 neg Absent - A 10 0.68 
35 29 M 80591 +
 
+
 
+ + none 35 0.4 13 1.6 2.4 neg Severe + C 21 0.76 
36 50 M 69630 +
 
+
 
- + none 27 0.6 6.4 1.2 3 neg Moderate + B 16 0.74 
37 49 M 77811 +
 
+
 
+ + Gr 1  34 0.4 5.4 2.1 2.3 neg Moderate - C 22 0.7 
38 69 M 61086 +
 
+
 
- - none 14 0.8 7.4 1.2 2.6 neg Absent - B 16 0.69 
39 54 M 83721 +
 
+
 
+ + none 27 0.5 12 1.7 2.4 neg Severe + C 23 0.79 
40 32 M 92863 +
 
+
 
+ + none 33 0.4 8.8 1.6 3 neg Severe + B 20 0.78 
41 45 M 67987 +
 
+
 
+ + Gr 2 31 1 9.6 2 2.9 neg Moderate + C 23 0.74 
42 25 M 63328 +
 
+
 
+ + Gr 1  41 1.3 14.3 1.3 2.5 neg Severe + C 25 0.74 
43 35 F 66173 - - - - none 36 1 1.8 1 3 HCV Absent - A 9 0.68 
44 46 M 76258 +
 
+
 
+ + none 26 0.4 9.3 1.9 1.8 neg Severe + C 22 0.79 
45 41 M 86470 +
 
+
 
+ + none 14 0.6 4.6 1.4 2.6 neg Moderate + B 16 0.71 
46 42 M 72655 +
 
+
 
+ + none 19 0.4 12.6 2.1 2.4 neg Severe + C 25 0.78 
47 47 M 75694 +
 
+
 
+ + none 49 0.6 5.5 1.4 3 neg Absent + A 17 0.72 
48 52 M 79169 +
 
+
 
+ + none 27 0.4 6.8 1.6 2.6 HbsAg Moderate + C 19 0.7 
49 41 M 74020 +
 
+
 
+ + none 21 0.9 8.6 1.7 2.8 neg Severe + C 23 0.8 
50 36 M 77739 +
 
+
 
+ + none 30 0.5 4.5 1.5 2.6 neg Absent - B 17 0.67 
51 45 M 89847 - - - - none 25 0.3 2.6 1.2 3.6 Neg Absent - A 12 0.69 
52 45 M 86248 +
 
+
 
+
 
+
 
Gr1 32 0.7 3.6 1.2 2.5 Neg Moderate + C 13 0.73 
53 53 M 71289 - +
 
- - none 26 0.6 3.4 1.6 2.7 HbsAg Mild + C 16   
54 37 M 64995 +
 
+
 
+
 
+
 
none 33 0.5 9.1 2.2 2.5 Neg Severe + C 24 0.76 
55 41 M 77301  +
 
- + + none 21 0.3 2.3 1.2 3.1 Neg Absent _ A 12 0.72 
 
 
56 30 M 86726  +
 
+
 
- - none 16 1 4.5 1.2 3.4 Neg Mild - B 14 0.7 
57 36 M 85154  +
 
+
 
+ + Gr 1  36 0.8 8.4 2.1 1.9 Neg Severe + C 23 0.79 
58 45 M 65349 - +
 
+ + none 21 0.4 3.2 1.4 2.4 HbsAg Moderate + A 15 0.74 
59 54 M 69396 - - - - none 32 0.6 3.2 1 2.9 HCV Mild - B 11 0.71 
60 26 M 76222  +
 
+
 
+ + Gr 1  31 0.7 13.8 1.8 2 Neg Severe + C 13 0.79 
61 51 F 69477 - +
 
+ + none 27 0.3 5.3 1.5 2 Neg Moderate + C 18 0.7 
62 46 M 83888 - +
 
+ + none 34 0.6 13 1.4 2.6 Neg Severe + C 20 0.74 
63 54 M 69838  +
 
- - - none 40 0.3 2.8 1.3 2.8 Neg Absent - A 13 0.69 
64 57 M 92236 - +
 
- + none 29 0.5 3.4 1.4 3 Neg Moderate + B 15 0.72 
65 45 M 74493  - +
 
+ + Gr 1  37 1.1 12.9 2.3 2.5 HbsAg Severe + C 27 0.76 
66 36 M 65697 +
 
+
 
- + none 32 0.4 7.2 1.4 3.5 Neg Mild - B 18 0.69 
67 34 M 77838 +
 
+
 
+
 
+
 
Gr 1  29 0.6 6.4 2.3 2.4 Neg Moderate - C 23 0.72 
68 48 M 78233 +
 
+
 
- + none 32 0.3 4.8 2.1 3 Neg Absent - B 13 0.73 
69 31 M 85172 +
 
+
 
+ + Gr 1  21 0.6 6.4 1.5 1.9 neg Severe + C 18 0.76 
70 43 M 88566 +
 
+
 
- + none 40 0.6 4.4 1.1 2.6 neg Moderate + C 13 0.74 
71 47 M 85592 +
 
+
 
- + none 26 0.4 5 1.4 2.8 neg Moderate + B 17 0.72 
72 54 M 81710 +
 
+
 
+ + Gr 1  40 0.6 10.8 2.1 2.1 HbsAg Severe + C 24 0.76 
73 68 F 78844 - +
 
+ + none 20 0.6 9.7 2.1 2.2 neg Severe + C 23 0.79 
74 29 F 69129 - - - - none 14 0.3 2.5 0.8 3.5 neg Absent - A 10 0.68 
75 56 M 63025 +
 
+
 
+ + GR1 35 0.4 13.4 1.9 2.4 neg Severe + C 24 0.73 
76 46 M 71251 +
 
+
 
- + none 27 0.6 6.4 1.2 3 neg Moderate + B 16 0.74 
77 67 M 62712 +
 
+
 
+ + none 34 0.4 5.4 2.1 2.3 neg Moderate - C 22 0.7 
78 48 M 93215 +
 
+
 
- - none 14 0.8 4.4 1.2 2.6 neg Absent - B 14 0.69 
79 50 M 79159 +
 
+
 
+ + none 27 0.5 6.4 1.3 2.4 neg Severe + C 16 0.79 
80 43 M 64224 +
 
+
 
+ + none 29 0.9 4.8 1.6 3 neg Severe + C 18 0.78 
81 46 M 82072 +
 
+
 
+ + none 31 1.1 13.5 2 2.9 neg Severe + C 25 0.74 
82 33 M 66749 +
 
+
 
+ + Gr 1  41 1 2.3 1.3 3 neg Mild + B 13 0.74 
83 55 F 77020 - - - - none 36 1 2.8 1.9 3 HCV Absent - A 18 0.68 
84 22 M 91778 +
 
+
 
+ + none 32 0.8 11.8 1.9 1.8 neg Severe + C 23 0.79 
85 65 M 87538 +
 
+
 
- + none 14 0.6 5.7 1.4 2.6 neg Moderate + B 17 0.71 
86 54 M 93223 +
 
- + + none 19 0.4 2.6 2.1 2.4 neg Severe + C 19 0.78 
87 43 M 69378 +
 
+
 
+ + none 31 0.6 7.7 1.4 3 neg Mild + B 18 0.72 
 
 
88 60 M 79407 +
 
+
 
+ + none 27 0.4 6.8 1.6 2.6 HbsAg Moderate + C 19 0.7 
89 56 M 67106 +
 
+
 
- - Gr 1  24 0.7 4.2 1.1 2.6 Neg Absent + C 13 0.76 
90 32 F 61616 - +
 
- +
 
none 32 0.7 7.8 1.4 2.6 Neg Moderate + B 18 0.72 
91 66 M 91736 +
 
+
 
+ + Gr 1  32 0.8 16.3 2.1 3 neg Severe + C 25 0.79 
92 75 M 80087 - +
 
+ + none 40 0.3 4.6 1.4 3.5 Neg Moderate + B 16 0.76 
93 17 M 64695 +
 
+
 
+ + none 42 0.5 12.4 2.3 2.3 neg Severe + C 25 0.75 
94 64 M 87865 - +
 
- + none 34 0.4 7.1 1.4 2.3 neg Moderate - C 18 0.69 
95 59 M 75742 +
 
+
 
+ + none 23 0.3 6.2 1.6 3.6 Neg Moderate + B 19 0.72 
96 41 M 65486 +
 
- - + none 28 0.6 2.4 1.4 2.8 neg Absent - B 14 0.7 
97 38 M 87474 +
 
+
 
+ + none 35 0.4 4.8 1.4 2.4 neg Moderate + C 16 0.72 
98 49 M 80797 +
 
+
 
+ + Gr 1  18 0.4 17.4 1.9 2.6 neg Severe + C 25 0.76 
99 53 F 78631 - +
 
- + none 23 0.6 8.5 1.1 2.8 neg Moderate + C 16 0.72 
100 28 M 87906 +
 
+
 
+
 
+
 
none 12 0.3 9.7 2.5 2.6 Neg Severe + C 25 0.71 
 
 
PHT – portal  hypertension 
PT INR – prothrombin time/ internationally normalised ratio  
CTP – child turcot pugh 
MELD – model for end stage liver disease 
Gr 1 – grade 1 
Gr 2 – grade 2 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
